This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O’Dwyer, P. J. et al. Nat. Med. 29, 1349–1357 (2023).
Bautista, F. et al. J. Clin. Oncol. 39, 3546–3560 (2021).
Morscher, R. J. et al. Eur. J. Cancer 157, 268–277 (2021).
Pasqualini, C. et al. Eur. J. Cancer 150, 53–62 (2021).
Geoerger, B. et al. Nat. Med. 29, 1358–1363 (2023).
Gatz, S. A. et al. CT087. Presented at the AACR Annual meeting, Orlando, FL, USA (2023).
Gatz, S.A. et al. CT088. Presented at the AACR Annual meeting, Orlando, FL, USA (2023).
Gatz, S. A. et al. CT019. Presented at the AACR Annual meeting, Orlando, FL, USA (2023).
Berlanga, P. et al. Cancer Discov. 12, 1266–1281 (2022).
Subbiah, V. Nat. Med. 29, 49–58 (2023).
Acknowledgements
We are grateful to all patients and their families who participated to the trial. We thank all treating teams of the pediatric phase 1 centers and their referring physicians for the stringent work that was brought into the trial and their confidence in the concept. We are also grateful to the Clinical Research Direction and the General Direction of the Gustave Roussy Cancer Campus for sponsorship and continuous support of our program. We are thankful to all pharmaceutical industry partners for providing their molecules and the extensive discussions with researchers to develop the most suitable design for the treatment arms. We are indebted to all funders for their confidence and support: Institut National de Cancer (INCa) within the AcSé program, Association Imagine for Margo, Fondation ARC, Federation Enfants et Santé, Société Française de lutte contre les Cancers et les leucémies de l’Enfant et l’adolescent (SFCE), Kick Cancer, Fondatioun Kriibskrank Kanner, Cancer Research UK, SEHOP and Fundación Pablo Ugarte. B.G. is supported by the ‘Parrainage médecin-chercheur’ of Gustave Roussy. The trial was in part developed in the Joint ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research held in Flims in 2014 (F.B., B.G., X.P.). The work was presented in part at the annual meetings of the AACR in 2017 in Washington, DC, USA, the ASCO 2019 in Chicago, USA, the SIOP 2019 in Lyon, France, and the AACR 2023 in Orlando, Florida, USA.
Author information
Authors and Affiliations
Contributions
B.G., X.P., F.B., S.A.G., L.V.M., N.A., P.Be., S.D., C.P., M.C., C.M.Z., K.N., J.R., D.V.-L. G., B.A., S.A., G.S., C.D. and G.V. conceived the study, provided and analyzed the data, and wrote the manuscript. P.Bl., N.H.-L. and A.B. provided funding. All authors approved the manuscript.
Corresponding author
Ethics declarations
Competing interests
B.G. has had an advisory role for AstraZeneca and Independent Data Monitoring Committee (IDMC) roles for trials sponsored by Roche and Novartis. S.A.G. has had an advisory role for EMD Serono/MERCK KGaA and AMGEN and received research funding (institution) from AstraZeneca, GSK and BAYER. L.V.M. has received Advisory Board Honoraria for Bayer, BMS, Day One Biopharmaceuticals, Eli Lilly, Illumina, Novartis and Tesaro and Paediatric Preceptorship/Chair and Speaker’s Honoraria from Bayer, and has been an IDMC member for clinical trials sponsored by Eisai and Merck. N.A. has had an advisory role for BAYER and Partners Therapeutics and receives grants (institution) from Bristol Myers Squibb and drugs for a trial from Bristol Myers Squibb, Pierre Fabre, Merck, Pfizer and travel support from Roche; he further has IDMC roles for Accord Healthcare. M.C. has had advisory roles for Astra Zeneca, Bayer and Pfizer and was an invited speaker for Bayer. K.N. serves on a data monitoring committee for Lilly.
Rights and permissions
About this article
Cite this article
Geoerger, B., Paoletti, X., Bautista, F. et al. AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial. Nat Med 29, 2985–2987 (2023). https://doi.org/10.1038/s41591-023-02580-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02580-5